Workflow
跃岭股份(002725) - 2025 Q4 - 年度业绩预告
2026-01-30 09:15
证券代码:002725 证券简称:跃岭股份 公告编号:2026-004 浙江跃岭股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况:预计净利润为正值且属于同向下降 50%以上情形 (1)以区间数进行业绩预告的 单位:万元 | 项 | 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的 | | | 1,200 | ~ | 1,800 | 4,719.45 | | 净利润 | | 比上年同期下降 | 61.86% | ~ | 74.57% | | | 扣除非经常性损益后的 | | | 270 | ~ | 405 | 482.33 | | 净利润 | | 比上年同期下降 | 16.03% | ~ | 44.02% | | | 基本每股收益(元/股) | | | 0.0469 | ~ | 0.0703 ...
宏桥控股(002379) - 2025 Q4 - 年度业绩预告
2026-01-30 09:15
证券代码:002379 证券简称:宏桥控股 公告编号:2026-018 山东宏桥铝业控股股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述或重大遗漏。 在业绩预告方面不存在分歧。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况:预计净利润为正值且属于扭亏为盈情形 以区间数进行业绩预告: 注:山东宏桥铝业控股股份有限公司(以下简称"公司")实施重大资产重组,通过发 行股份的方式购买山东宏拓实业有限公司(以下简称"宏拓实业")100%股权,于 2025 年 12 月 31 日完成资产交割及股权工商变更等相关工作,宏拓实业纳入公司合并报表范围。由 于本公司与宏拓实业属于同一最终控制方,本次交易构成同一控制下的企业合并,根据企业 会计准则的规定,公司已对上年同期财务数据进行了追溯调整。上述调整后的上年同期数据 未经审计。 报告期内,宏拓实业纳入公司合并报表范围。根据《公开发行证券的公司信息披露解释 性公告第 1 号——非经常性损益》的相关规定,同一控制下企业合并产生的子公 ...
万东医疗(600055) - 2025 Q4 - 年度业绩预告
2026-01-30 09:15
证券代码:600055 证券简称:万东医疗 公告编号:2026-009 北京万东医疗科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示: 业绩预告的具体适用情形:净利润为负值。 北京万东医疗科技股份有限公司(以下简称"公司")预计2025年 度实现归属于母公司所有者的净利润为-19,873万元到-25,683万元。预计 2025年度实现归属于母公司所有者的扣除非经常性损益后的净利润为 -21,323万元到-27,133万元。 一、本期业绩预告情况 (一)业绩预告期间 2025年1月1日至2025年12月31日。 (二)业绩预告情况 经财务部门初步测算,预计 2025 年度实现归属于母公司所有者的净利 润为-19,873 万元到-25,683 万元,与上年同期相比,将出现亏损。 预计 2025 年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-21,323 万元到-27,133 万元,与上年同期相比,将出现亏损。 二、上年同期经营业绩和财务状况 (一)公司 2 ...
移为通信(300590) - 2025 Q4 - 年度业绩预告
2026-01-30 09:14
Financial Projections - The estimated net profit for 2025 is projected to be between ¥66.62 million and ¥82.48 million, representing a decrease of 58.00% to 48.00% compared to the previous year[5]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between ¥52.46 million and ¥66.64 million, reflecting a decline of 63.00% to 53.00% year-on-year[5]. - The company's comprehensive gross profit margin is expected to maintain around 40%[5]. - The revenue decline has been narrowing in Q3 and is expected to continue improving through the year[5]. - The financial data presented is preliminary and has not been audited by an accounting firm[4]. - The detailed financial data will be disclosed in the 2025 annual report[7]. Operational Challenges - Increased R&D expenses due to a rise in project approvals and personnel investment, alongside higher marketing costs for regional market development[6]. - The company has faced challenges such as inventory impairment provisions, decreased government subsidies, and delayed order shipments affecting net profit[6]. - The global trade environment has been pressured by U.S. tariff policy adjustments and geopolitical conflicts, impacting revenue[5]. Strategic Initiatives - The company is implementing a "four new" development strategy focusing on new businesses, products, application scenarios, and customers[6].
新巨丰(301296) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
证券代码:301296 证券简称:新巨丰 公告编号:2026-006 山东新巨丰科技包装股份有限公司 2025 年度业绩预告 注:1、报告期内公司完成了通过下属全资子公司景丰控股有限公司向香港联交所上市 公司纷美包装有限公司(以下简称纷美包装、标的资产)全体股东通过自愿有条件全面要约 及/或通过其他符合监管要求的形式现金收购纷美包装已发行股份(要约人及其一致行动人 持有的股份除外)的重大资产购买项目,标的资产自2025年4月1日起纳入公司合并报表范围。 2、上年同期重组后的数据系假设上年同期已经完成该重大资产购买项目的备考审阅报 告数据;本报告期仅包含标的资产2025年4月1日起至12月31日的数据。 3、标的资产国际业务的估值影响未包含在业绩预告中。 4、本表数据为合并财务报表数据,本公告中的"万元"指人民币。 二、与会计师事务所沟通情况 本次业绩预告是公司财务部门初步测算的结果,公司已就业绩预告有关事项 与会计师事务所进行了预沟通,公司与会计师事务所在业绩预告方面不存在重大 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告 ...
霍普股份(301024) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
Financial Performance - The company expects a net profit in the range of -85 million to -65 million CNY for the fiscal year 2025, representing a year-on-year increase of 24.91% to 42.58% compared to the previous year's net profit of -113.2 million CNY[4] - The net profit after deducting non-recurring gains and losses is projected to be between -87 million and -67 million CNY, showing a year-on-year growth of 22.59% to 40.38% from -112.4 million CNY last year[4] - The company's operating revenue is estimated to be between 130 million and 160 million CNY, which is slightly lower than the previous year's revenue of 138.6 million CNY[4] Sector Performance - The architectural green energy sector is experiencing good growth, with increased revenue due to the expansion of development, construction, and operation scales in solar storage charging[6] - The architectural design sector has faced revenue declines due to intensified market competition and extended implementation cycles[7] Impairment and Auditing - The company plans to recognize impairment losses on goodwill related to previous acquisitions, with the final impairment amount to be determined by an evaluation and audit by appointed agencies[7] - The financial data presented is preliminary and has not been audited by the accounting firm, and the company has communicated with the auditors regarding the earnings forecast without major discrepancies[5] Investor Guidance - Investors are advised to refer to the company's 2025 annual report for specific financial data and to exercise caution in their investment decisions[8]
翰博高新(301321) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
证券代码:301321 证券简称:翰博高新 公告编号:2026-006 2、业绩预告情况:预计净利润为负值 | 项目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利 润 | 亏损:5,500 | 万元-9,000 万元 | 亏损:21,480.83 | 万元 | | 归属于上市公司股东的扣除 非经常性损益后的净利润 | 亏损:7,700 | 万元-12,000 万元 | 亏损:23,669.41 | 万元 | 二、与会计师事务所沟通情况 本次业绩预告的相关财务数据未经会计师事务所审计,但公司已就本次业绩 预告相关事项与会计师事务所进行了预沟通,公司与会计师事务所在业绩预告相 关财务数据方面不存在分歧。 三、业绩变动原因说明 报告期内,公司归属于上市公司股东的净利润为负值,但较上年同期减亏显 著。主要原因为: 翰博高新材料(合肥)股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 ...
英华特(301272) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
证券代码:301272 证券简称:英华特 公告编号:2026-002 苏州英华特涡旋技术股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况:预计净利润为正值且属于同向下降 50%以上情形 (1)以区间数进行业绩预告的 单位:万元 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的 | | 2,700 | ~ | 3,800 | 7,416.54 | | 净利润 | 比上年同期下降 | 48.76% | ~ | 63.59% | | | 扣除非经常性损益后的 | | 1,900 | ~ | 2,700 | 6,121.01 | | 净利润 | 比上年同期下降 | 55.89% | ~ | 68.96% | | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果,未经会计师事务 ...
迪瑞医疗(300396) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
Financial Performance - The company expects a net profit of approximately -35,000 million CNY for the fiscal year 2025, compared to -18,000 million CNY in the same period last year, indicating a significant decline [5]. - The net profit after deducting non-recurring gains and losses is projected to be around -36,000 million CNY, down from -18,500 million CNY year-over-year [5]. - The decline in performance is attributed to intensified market competition, asset impairment, and adjustments in product pricing, which negatively impacted revenue and profit margins [8]. Cash Flow and Cost Management - The company has improved cash flow significantly, with collections and cost control measures leading to a substantial increase compared to the previous year [9]. - The company is committed to enhancing its product intelligence and market expansion while continuing to strengthen internal controls and cost reduction efforts [10]. International Expansion - The company has been actively expanding its international market presence, maintaining a solid foundation in over 120 countries, and plans to deepen its focus on 10 selected countries as part of its "2+2+10" international strategy [10]. Product Development and Innovation - The company is focusing on technological innovation and product development, with 14 new products, including the CS-1300A automatic biochemical analyzer, launched during the reporting period [10]. Earnings Forecast and Investor Advisory - The company has communicated with its accounting firm regarding the earnings forecast, and there are no significant discrepancies reported [6]. - The financial data presented is preliminary and subject to final confirmation in the official 2025 annual report [11]. - Investors are advised to exercise caution and consider investment risks based on the preliminary earnings forecast [11].
安联锐视(301042) - 2025 Q4 - 年度业绩预告
2026-01-30 09:12
证券代码:301042 证券简称:安联锐视 公告编号:2026-002 珠海安联锐视科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 一、 本期业绩预计情况 单位:万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | 2,000 | ~ | 2,400 | 7,133.32 | | | 比上年同期下降 | 71.96% | ~ | 66.36% | | | 扣除非经常性损 | | 1,800 | ~ | 2,300 | 6,455.31 | | 益后的净利润 | 比上年同期下降 | 72.12% | ~ | 64.37% | | 二、与会计师事务所沟通情况 本次业绩预告相关数据是珠海安联锐视科技股份有限公司(以下 简称"公司")财务部门初步测算的结果,未经会计师事务所审计。 公司已就业绩预告情况与年审会计师事务所进行预沟通,公司与年审 会计师事务所在业绩预告方面不存在分歧。 三、业绩变动原因说明 ...